NASDAQ:STRO • US8693672011
Past quarterly earnings results for SUTRO BIOPHARMA INC (STRO), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -6.70 | -4.23 | -58.49% | -13.56% | 9.693M | 9.314M | 4.07% | 13.77% |
| Q2 2025 | -1.40 | -4.10 | 65.88% | 76.27% | 63.745M | 14.538M | 338.47% | 147.98% |
| Q1 2025 | -9.10 | -7.22 | -26.10% | 4.21% | 17.399M | 11.843M | 46.91% | 33.76% |
| Q4 2024 | -8.90 | -8.48 | -4.99% | -271.15% | 14.809M | 12.685M | 16.74% | -86.98% |
| Q3 2024 | -5.90 | -7.49 | 21.27% | 27.16% | 8.52M | 15.558M | -45.24% | -49.66% |
| Q2 2024 | -5.90 | -8.08 | 26.97% | 7.81% | 25.706M | 21.441M | 19.89% | 146.89% |
| Q1 2024 | -9.50 | -9.40 | -1.02% | -11.76% | 13.008M | 12.312M | 5.65% | 2.64% |
| Q4 2023 | 5.20 | -8.40 | 161.92% | 176.47% | 113.721M | 12.044M | 844.21% | 1,217.74% |
| Q3 2023 | -8.10 | -7.51 | -7.90% | -118.92% | 16.924M | 13.259M | 27.64% | -32.71% |
| Q2 2023 | -6.40 | -7.47 | 14.34% | -16.36% | 10.412M | 12.808M | -18.71% | -62.95% |
| Q1 2023 | -8.50 | -8.28 | -2.70% | -1.19% | 12.674M | 11.373M | 11.44% | 114.81% |
| Q4 2022 | -6.80 | -6.34 | -7.31% | 18.07% | 8.63M | 14.768M | -41.56% | -18.97% |
| Q3 2022 | -3.70 | -7.53 | 50.87% | 44.78% | 25.15M | 12.932M | 94.48% | 195.19% |
| Q2 2022 | -5.50 | -4.71 | -16.86% | -323.08% | 28.1M | 17.021M | 65.09% | 0.18% |
| Q1 2022 | -8.40 | -7.73 | -8.72% | -27.27% | 5.9M | 10.675M | -44.73% | -59.75% |
| Q4 2021 | -8.30 | -7.03 | -18.15% | 43.92% | 10.65M | 10.865M | -1.98% | 28.62% |
| Q3 2021 | -6.70 | -6.64 | -0.86% | -248.89% | 8.52M | 9.148M | -6.86% | -52.19% |
| Q2 2021 | -1.30 | -4.22 | 69.20% | 77.97% | 28.05M | 13.605M | 106.17% | 196.20% |
| Q1 2021 | -6.60 | -6.15 | -7.28% | 21.43% | 14.66M | 5.843M | 150.90% | 105.03% |
| Q4 2020 | -14.80 | -5.81 | -154.56% | - | 8.28M | 9.575M | -13.52% | - |
| Q3 2020 | 4.50 | -5.17 | 186.99% | - | 17.82M | 8.67M | 105.54% | - |
| Q2 2020 | -5.90 | -6.57 | 10.15% | - | 9.47M | 8.128M | 16.51% | - |
| Q1 2020 | -8.40 | -7.02 | -19.60% | - | 7.15M | 10.909M | -34.46% | - |
Notes
SUTRO BIOPHARMA INC (STRO) last reported earnings on 11/6/2025.
SUTRO BIOPHARMA INC (STRO) missed EPS estimates and beat revenue estimates in the most recent quarter.
In the last 4 quarters, SUTRO BIOPHARMA INC (STRO) has beaten EPS estimates in 1 out of 4 releases.